A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD

This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease. This was a 12-week, multicentre, randomised, open-label, parallel-group study (Clinicaltrials.gov: NCT0223661...

Descripción completa

Detalles Bibliográficos
Autores principales: Rheault, Tara, Khindri, Sanjeev, Vahdati-Bolouri, Mitra, Church, Alison, Fahy, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005182/
https://www.ncbi.nlm.nih.gov/pubmed/27730198
http://dx.doi.org/10.1183/23120541.00101-2015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005182/
https://www.ncbi.nlm.nih.gov/pubmed/27730198
http://dx.doi.org/10.1183/23120541.00101-2015

Ejemplares similares